Serial Entrepreneur
Female Founder
Exited FounderAbout
machineMD is a Swiss-based neurodiagnostics startup pioneering a new era of healthcare from the eye through oculometrics — the quantitative assessment of eye and pupillary movements to support early neurological diagnosis and monitoring. Our flagship medical device, neos®, combines advanced infrared eye tracking, virtual reality (VR), and a proprietary software platform powered by AI-driven analytics to enable non-invasive, fast, and quantitative eye-function assessments in a standardized manner. By making neuro-ophthalmic expertise more accessible in primary and secondary care settings, machineMD aims to expand access to objective neurological assessment tools beyond tertiary centers. In parallel, we are advancing the use of oculometric biomarkers in clinical research and drug development, enabling scalable and quantitative functional endpoints for neurological and neurodegenerative therapeutic innovation.
Products
neos
Our flagship medical device, neos® — the world’s first neuro-ophthalmoscope — combines a lightweight head-mounted VR display with 200 Hz infrared eye tracking, proprietary visual stimuli, and AI-driven analytics to enable non-invasive, fast, and standardized neuro-ophthalmic assessments. neos® quantitatively evaluates multiple aspects of neuro-ophthalmic function, including eye movements, pupillary responses, ocular alignment, smooth pursuit, saccades, and visual field performance, generating objective functional biomarkers that can support neurological screening, diagnosis, monitoring, and research. Through its cloud-based software platform, neos® processes examination data in real time and generates user-friendly reports within minutes, enabling secure integration into electronic health record systems and remote specialist review through tele-neuro-ophthalmology workflows. By digitizing and automating examinations that traditionally require highly specialized expertise, neos® helps expand access to neuro-ophthalmic assessment across primary, secondary, and tertiary care settings. Beyond clinical care, machineMD is also advancing the use of oculometric biomarkers in clinical research and drug development, enabling objective and scalable functional endpoints for neurological and neurodegenerative therapeutic innovation.
Click to read more